Sanofi Stock Breaks Bollinger Bands After Record Quarter for Dupixent
Sanofi made significant gains this Thursday, driven by the release of its first quarter 2026 results and favorable news surrounding its flagship product Dupixent. The stock is trading at €83.48, up 3.34% from the previous day's close, in a Parisian market trending upwards with the CAC 40 gaining 0.46% during the session.
Strong Quarterly Performance and Regulatory Approval Boost Sanofi
This morning, Sanofi revealed a quarterly revenue increase of 13.6% at constant exchange rates, supported by the momentum of its pharmaceutical launches and the integration of its recent acquisitions. The net earnings per share from operations grew by 14%, thanks notably to a disciplined approach to operational expenses, which increased by only 7%. The blockbuster Dupixent surpassed the symbolic threshold of 4 billion euros in revenue for the quarter. For the fiscal year 2026, the group maintains its forecast for sales growth at the upper end of the single-digit range.
In parallel, the FDA granted Dupixent its first approval for pediatric chronic spontaneous urticaria in children aged two to eleven years, a condition for which no biological treatment had previously been approved in the United States. This market expansion broadens the commercial potential of the drug, which is the main growth driver for the group.
Technical Indicators Suggest Overbought Condition
With a price of €83.48, the stock now exceeds the upper boundary of the Bollinger Bands, set at €83.46, indicating a potential technical overbought signal. This breakthrough occurs as the stock also trades above its 20-day moving average (€81.10) and 50-day moving average (€79.58), confirming a short-term bullish trend. However, the RSI at 51 remains in the neutral zone, tempering the interpretation of excessive enthusiasm.
The stock has gained 2.92% over the past seven days and 4.66% over three months, but still shows a decline of 8.43% over one year. The beta of 0.23 indicates low sensitivity to market fluctuations, which partly explains the stock's relatively independent behavior compared to the overall market. Among European peers, UCB was up 0.90% in session while Argenx SE dropped 0.50%. Across the Atlantic, Eli Lilly had closed up 2.04%, while AbbVie had fallen by 2.25%.
